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http:WHAT THIS PAPER ADDS
This study evaluated 1 year changes in health status in patients with new onset or an exacerbation of peripheral
arterial disease (PAD) symptoms. Thirty-nine per cent were referred for invasive treatment. Invasive treatment
was offered across the whole spectrum of pre-procedural health status scores. Patients within the lowest
quartile of pre-procedural health status scores had the greatest improvements, whereas those in highest
quartiles did not improve substantially. One year invasive treatment and lower pre-procedural health status
scores were independent associates for greater 1 year health status gains. This information may help to facilitate
the discussion between patients and PAD specialists about which treatments should be considered for the
patients’ PAD.Objective/Background: Limited information is available on expected health status gains following invasive
treatment in peripheral arterial disease (PAD). One year health status outcomes following invasive treatment for
PAD were compared, and whether pre-procedural health status was indicative of 1 year health status gains was
evaluated.
Methods: Pre-procedural and 1 year health status (Short Form-12, Physical Component Score [PCS]) was
prospectively assessed in a cohort of 474 patients, enrolled from 2 Dutch vascular clinics (March 2006eAugust
2011), with new or exacerbation of PAD symptoms. One year treatment strategy (invasive vs. non-invasive) and
clinical information was abstracted. Quartiles of baseline health status scores and mean 1 year health status
change scores were compared by invasive treatment for PAD. The numbers needed to treat (NNT) to obtain
clinically relevant changes in 1 year health status were calculated. A propensity weight adjusted linear regression
analysis was constructed to predict 1 year PCS scores.
Results: Invasive treatment was performed in 39% of patients. Patients with baseline health status scores in the
lowest quartile undergoing invasive treatment had the greatest improvement (mean invasive 11.3  10.3 vs.
mean non-invasive 5.3  8.5 [p ¼ .001, NNT ¼ 3]), whereas those in the highest quartile improved less (.8  6.3
vs. e3.0  8.2 [p ¼ .025, NNT ¼ 90]). Undergoing invasive treatment (p < .0001) and lower baseline health
status scores (p < .0001) were independently associated with greater 1 year health status gains.
Conclusion: Substantial improvements were found in patients presenting with lower pre-procedural health status
scores, whereas patients with higher starting health status levels had less to gain by an invasive strategy.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The goals of treatment in symptomatic lower extremity
peripheral arterial disease (PAD; Fontaine 2, mild to mod-
erate symptoms of claudication) are to alleviate patients’
symptoms and to improve their health status.1e5 Despite
these objectives, patients’ health status may not always be
214 M. van Zitteren et al.a decisive factor in referring patients for invasive treat-
ment.6 In addition, in large clinical trials, outcomes of in-
terest were often focused on hemodynamic success rates,7e
9 as opposed to clinically meaningful improvements in pa-
tients’ health status.
It is also unclear whether invasive treatment is being
applied in patients for whom the greatest health status
beneﬁt can be expected. One of the factors that may
predict health status outcomes following invasive treat-
ment is pre-procedural health status. In coronary disease,
patients with lower health status scores undergoing
percutaneous coronary intervention had the most to gain
from this treatment when comparing their health status
improvements with those having high pre-procedural
health status scores.10 This has never been evaluated for
invasive treatments. It is also unknown whether invasive
treatments are offered to patients with PAD across the
whole spectrum of pre-procedural health status scores in
daily practice.
Given these gaps in knowledge and the rapid increase in
use of endovascular procedures and its associated costs,11e
13 it seems desirable to quantify and predict expected
health status beneﬁts by treatment strategy based on pre-
procedural, measurable characteristics such as patients’
health status. This study documented invasive treatment
rates as a function of patients’ pre-procedural health status,
and quantiﬁes the magnitude of 1 year beneﬁts in patients’
self reported health status across the range of pre-
procedural health status scores.
METHODS
Study population and design
In this prospective observational study, 474 consecutive
patients with new onset symptomatic lower extremity PAD
or worsening of existing exertional PAD symptoms requiring
new clinical work (Fontaine 2, mild to moderate symptoms
of claudication) were enrolled in the period March 2006e
August 2011 from two vascular surgery outpatient clinics
(St. Elisabeth Hospital and TweeSteden Hospital, Tilburg, the
Netherlands) (Appendix I). Patients were eligible for inclu-
sion if they presented with exertional leg symptoms and if
their resting ankle brachial index (ABI) was abnormal
(0.90) or decreased 15% from the resting ABI following a
distance limited treadmill test. Exclusion criteria were a
non-compressible ABI (1.30), critical limb ischemia, severe
cognitive impairment or severe somatic or psychiatric
comorbidities, insufﬁcient knowledge of the Dutch lan-
guage, or other reasons (e.g., participation in another study,
treatment started before study inclusion). Patients were
additionally excluded if: (i) patients had >25% missing
values on their health status assessments; (ii) patients died
during the ﬁrst year of follow up; or if (iii) no pre-procedural
duplex ultrasound examination was available in the pa-
tients’ medical charts 3 months prior to or after inclusion.
All patients underwent a vascular diagnostic work up on
enrollment, including a clinical evaluation by their treating
vascular surgeon (Appendix II).The local ethics committee of each participating institu-
tion approved the study, which was designed in line with
the Declaration of Helsinki. All participants provided written
informed consent. Study participation did not inﬂuence the
type of treatment patients received because the study was
observational in nature.Measures
Assessment of health status. The Dutch version of the
Short Form 12 (SF-12), a generic health status instru-
ment,2,14 was used to assess patients’ self reported pre-
procedural (i.e., prior to treatment), and 1 year physical
and mental health status (Physical Component Summary
[PCS] score and Mental Component Summary (MCS) score).
PCS and MCS scores (range 0e100, mean  SD score
50  10) were standardized against the Dutch general
population norms.15 Higher scores were indicative of better
physical and mental functioning.15 Based on ranges of
scores to expect following invasive treatment in PAD in
similar populations,4,16e18 clinically relevant changes based
on a 1 year change score (1 year health status score minus
pre-procedural health status score) falling within the range
of 0.5 SD (5 points) and 1.0 SD (10 points) were
calculated. All treating vascular specialists were blinded to
the initial SF-12 score, as this could have had the potential
to inﬂuence the decision making process.
One year treatment strategies. A variety of treatment
strategies were available at both enrolling centers, including
non-invasive strategies: a formal supervised exercise ther-
apy program supported by a regional network of certiﬁed
physiotherapists; smoking cessation counseling; and
optimal medical care (e.g., aspirin, anticoagulants, and
statins).6 Treatments were categorized for analytical pur-
poses: if no hospital admissions for vascular reasons were
documented within the ﬁrst year following diagnosis, pa-
tients were considered to have had non-invasive treatment
options only. Patients were assigned to the invasive treat-
ment category if any invasive lower extremity procedure
was documented in their medical records.6 Patients
received care for their PAD at the vascular surgery depart-
ment. In any case, medical management of cardiovascular
risk factors was initiated or sustained for all patients, and
exercise therapy was also made available, regardless of
whether patients were referred for invasive therapy for
their PAD symptoms.
Disease severity. A handheld Doppler instrument (Imexlab
9000; Imex Medical Systems Inc., Golden, CO, USA) was
used by trained vascular technicians to conﬁrm the PAD
diagnosis by measuring patients’ resting and post-exercise
ABI following a distance limited treadmill test.
Duplex ultrasound examination protocol. Based on his/her
clinical evaluation during the diagnostic work up, a duplex
ultrasound examination of the lower extremities was or-
dered by the treating vascular surgeon. Trained vascular
technicians performed the ultrasounds with the Toshiba
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Europe, Zoetermeer, the Netherlands) from which lesion
information was derived (i.e., anatomical location, and the
number and severity of lesions). Lesion severity was
measured by the peak systolic velocity (PSV [cm/s]) ratio,
where a PSV ratio 2.5, or total occlusions, were consid-
ered signiﬁcant. Lesions were scored as proximal or distal
lesions only, having both proximal and distal lesions, or
having non-signiﬁcant lesions. A detailed description of the
duplex ultrasound protocol has been published
elsewhere.19
Clinical risk factors. Information on clinical risk factors was
abstracted from patients’ medical records and included
cardiac history, cerebrovascular history, current smoking,
diabetes mellitus, dyslipidemia, hypertension, body mass
index (BMI; kg/m2), chronic obstructive pulmonary disease
(COPD), renal dysfunction, back pain, and knee/hip osteo-
arthritis. In addition, patients’ medication use following
their vascular diagnostic evaluation was also abstracted.
Socio-demographic and psychological factors. Patients’ age
and sex was documented through medical chart abstrac-
tion. Information on socio-demographic factors was derived
from self report questionnaires that patients completed on
enrollment, and included marital status (no partner vs.
partner), educational background (<high school vs. high
school education), and work status (non-active vs. active
work status). The presence of clinically relevant depression
and anxiety was assessed by the Hospital Anxiety and
Depression Scale using cut off scores 8 on both the anx-
iety and depression subscale.20Statistical analysis
Patient baseline characteristics, as well as 1 year PCS
change scores, were described for the total population and
compared by quartiles of pre-procedural PCS scores. Inva-
sive treatment rates were compared by quartiles of pre-
procedural PCS and MCS scores to gain additional insights
into differences in mental and physical health status. The
chi-square test, ANOVA, and the KruskaleWallis test were
used for descriptive purposes, as appropriate.
To quantify the magnitude of the health status change
effects at 1 year following treatment referral, effect sizes
(Cohen’s D) were calculated for patients who underwent
invasive vs. non-invasive treatment by quartiles of their pre-
procedural PCS scores. Similarly, the number needed to
treat (NNT) to obtain a clinically relevant improvement in
physical health status falling within the range of 0.5 SD (5
points) and 1.0 SD (10 points) was calculated for quartiles
of pre-procedural PCS scores. The NNT is deﬁned as the
number of persons needed to treat to prevent one
outcome, and is calculated by the inverse of the absolute
risk reduction.21,22
Since the study was observational in nature, propensity
weights were calculated for all patients using all baseline
characteristics for the propensity to undergo invasive versus
non-invasive treatment. A propensity adjusted linearregression model was constructed to examine the associa-
tion between treatment strategy (invasive vs. non-invasive),
pre-procedural health status, and 1 year PCS change scores.
The model was sequentially built by the following steps: (i)
treatment strategy (invasive vs. non-invasive), pre-proce-
dural PCS scores (to control for regression towards the
mean), and the interaction between treatment strategy and
pre-procedural PCS scores; (ii) demographics (age, sex),
hospital site, marital status, educational background; (iii)
anatomical lesion location, resting ABI; (iv) cardiac history,
cerebrovascular history, current smoking, diabetes mellitus,
BMI, renal dysfunction, COPD, back pain, and hip/knee
osteoarthritis; and (v) depression. Finally, the explained
variance (R2) was calculated for all individual variables
included in the model.
Missing SF-12 items were handled by multiple imputation
(mean of ﬁve iterations) if 75% of all items were
completed. Missing items were assumed to be missing at
random. A total of 16 patients had <25% missing values at
both baseline and 1 year follow up. Compared with the
other 458 patients, these 16 were slightly older (p ¼ .005,
Cohen’s D ¼ .8) and more likely to use anticoagulants
(p ¼ .040, Cramér’s V ¼ .099). They were similar in terms of
all other characteristics. A sensitivity analysis was per-
formed based on complete case analyses.
PASW Statistics 19.0 for Windows (SPSS, IBM, Armonk,
NY, USA) was used to perform all analyses. All tests were
two-tailed and statistical signiﬁcance was considered as a p
value <.05.RESULTS
Baseline characteristics
Table 1 presents patient characteristics for the total sample
(n ¼ 474), stratiﬁed by quartiles of pre-procedural health
status scores. The mean age of the cohort was 65 years and
67% were male.
Patients with lower health status scores were more likely
to have a lower educational status, a history of cardiovas-
cular disease, other comorbidities or risk factors, and to
receive cardioprotective medications and psychopharmaca
than patients having higher health status scores. While the
ABI did not differ across health status categories, patients
with lower health status scores were more likely to have a
shorter pain free walking distance, to have undergone a
prior lower extremity surgical intervention, and to present
with a proximal or non-signiﬁcant lesion than those with
higher health status scores. Also, the presence of psycho-
logical comorbidities increased along with decreasing health
status scores.Physical health status scores by the receipt of 1 year
invasive treatment
A total of 183 (39%) patients underwent invasive treatment
1 year following diagnosis, ranging from 41% to 46% in
the lowest three physical health status quartiles to 24% in
the highest (p ¼ .001). In line with the comparisons for the
Table 1. Baseline characteristics of the total sample and stratiﬁed by quartiles of baseline health status scores (physical component
scores).a
Total sample
(n ¼ 474)
Quartile 1
(n ¼ 119)b
Quartile 2
(n ¼ 118)c
Quartile 3
(n ¼ 119)d
Quartile 4
(n ¼ 118)e
p
Demographics
Age, y (mean  SD) 65.0  9.4 63.8  11.1 65.3  9.3 65.1  8.5 65.8  8.6 .40
Male sex 315 (66.5) 69 (58.0) 76 (64.4) 82 (68.9) 88 (74.6) .06
Socioeconomic factors
No partner 112 (23.9) 33 (27.7) 29 (24.8) 26 (22.4) 24 (20.5) .61
Less than high
school education
116 (24.9) 39 (33.1) 33 (28.9) 23 (20.0) 21 (17.8) .023
Non-active work status 335 (73.6) 88 (77.2) 84 (73.7) 87 (77.6) 76 (64.5) .07
Cardiovascular history
Angina pectoris 65 (13.7) 16 (13.5) 19 (16.1) 17 (14.3) 13 (11.0) .74
Myocardial infarction 87 (18.4) 22 (18.5) 28 (23.7) 25 (21.0) 12 (10.2) .043
CABG 58 (12.2) 13 (10.9) 21 (17.8) 16 (13.5) 8 (6.8) .07
PCI 46 (9.7) 14 (11.8) 15 (12.7) 8 (6.7) 9 (7.6) .25
Congestive heart failure 21 (4.4) 8 (6.7) 8 (6.8) 3 (2.5) 2 (1.7) .08
Stroke 39 (8.2) 10 (8.4) 15 (12.7) 11 (9.2) 3 (2.5) .043
TIA 41 (8.7) 9 (7.6) 14 (11.9) 10 (8.4) 8 (6.8) .55
Clinical factors
Smoking 220 (46.4) 59 (49.6) 48 (40.7) 50 (42.0) 63 (53.4) .13
Diabetes mellitus 108 (22.8) 33 (27.7) 35 (29.7) 27 (22.7) 13 (11.0) .003
Hypercholesterolemia 327 (69.0) 84 (70.6) 87 (73.7) 80 (67.2) 76 (64.4) .48
Hypertension 285 (60.1) 67 (56.3) 77 (65.3) 82 (68.9) 59 (50.0) .016
BMI (mean  SD) 26.8 (4.7) 27.9 (6.6) 26.5 (4.1) 27.1 (4.0) 25.9 (3.3) .011
COPD 78 (16.5) 29 (24.4) 26 (22.0) 14 (11.8) 9 (7.6) < .001
Renal dysfunction 44 (9.3) 12 (10.1) 14 (11.9) 12 (10.1) 6 (5.1) .35
Back pain 69 (14.6) 35 (29.4) 15 (12.7) 11 (9.2) 8 (6.8) <.0001
Hip or knee osteoarthritis 98 (20.7) 33 (27.7) 26 (22.0) 19 (16.0) 20 (17.0) .10
Vascular laboratory assessment
PFWD, m (median  SD) 80.0 ± 123.9 70.0 ± 67.1 80.0 ± 120.0 80.0 ± 136.9 100.0 ± 147.6 < .0001
Resting ABI (mean  SD)f 65.9  16.6 63.2  18.2 66.7  17.7 68.1  14.6 65.8  15.2 .13
Fontaine II class
Fontaine IIB 200 m 411 (86.8) 114 (96.6) 102 (87.2) 102 (87.9) 93 (79.6) .06
Fontaine IIA >200 m 57 (12.2) 4 (3.4) 15 (12.8) 14 (12.1) 24 (20.4)
Prior lower extremity
revascularization
Endovascular 60 (12.7) 23 (19.3) 13 (11.0) 14 (11.8) 10 (8.5) .07
Surgery 33 (7.0) 17 (14.3) 8 (6.8) 5 (4.2) 3 (2.5) .002
Anatomical lesion location .021
Proximal 129 (28.5) 34 (31.8) 36 (31.9) 34 (29.1) 25 (21.7)
Distal 234 (51.8) 46 (43.0) 53 (46.9) 60 (51.3) 75 (65.2)
Proximal and distal, 44 (9.7) 9 (8.4) 11 (9.7) 13 (11.1) 11 (9.6)
Non-signiﬁcant 45 (10.0) 18 (16.8) 13 (11.5) 10 (8.6) 4 (3.4)
Medication use
Aspirin 368 (77.6) 90 (75.6) 93 (78.8) 93 (78.2) 92 (78.0) .96
Anticoagulants 78 (16.5) 25 (21.0) 27 (22.9) 14 (11.8) 12 (10.2) .013
Statins 391 (82.5) 98 (82.4) 102 (86.4) 101 (84.9) 90 (76.3) .20
Beta blocker 205 (43.2) 49 (41.2) 62 (52.5) 53 (44.5) 41 (34.7) .050
Diuretics 113 (23.8) 35 (29.4) 32 (27.1) 30 (25.2) 16 (13.6) .025
ACE inhibitor 157 (33.1) 45 (37.8) 44 (37.3) 39 (32.8) 29 (24.6) .11
Calcium antagonist 102 (21.5) 25 (21.0) 26 (22.0) 35 (29.4) 16 (13.6) .024
Nitroglycerine 42 (8.9) 16 (13.5) 12 (10.2) 10 (8.4) 4 (3.4) .050
Digoxin 9 (1.9) 3 (2.5) 3 (2.5) 3 (2.5) 0 (0.0) .34
Antiarrhythmics 12 (2.5) 5 (4.2) 3 (2.5) 3 (2.5) 1 (0.9) .44
Antidepressants 26 (5.5) 15 (12.6) 4 (3.4) 4 (3.4) 3 (2.5) .001
Anxiolytics 19 (4.0) 8 (6.7) 7 (5.9) 2 (1.7) 2 (1.7) .10
Hypnotics 22 (4.6) 10 (8.4) 7 (5.9) 4 (3.4) 1 (0.9) .035
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Table 1-continued
Total sample
(n ¼ 474)
Quartile 1
(n ¼ 119)b
Quartile 2
(n ¼ 118)c
Quartile 3
(n ¼ 119)d
Quartile 4
(n ¼ 118)e
p
Psychological factors
Depression 131 (27.9) 62 (52.1) 36 (30.8) 25 (21.6) 8 (6.8) < .0001
Anxiety 109 (23.2) 45 (37.8) 29 (24.8) 30 (25.9) 5 (4.2) < .0001
Note. Data are given as n (%) unless otherwise indicated. Values in bold indicate statistical signiﬁcance. CABG ¼ coronary artery bypass
graft; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic attack; COPD ¼ chronic obstructive pulmonary disease;
PFWD ¼ pain free walking distance; ABI ¼ ankle brachial index; ACE ¼ angiotensin converting enzyme inhibitor.
a Calculated column percentages for patient characteristics may deviate in case different denominators (owing to missingness) were used.
b Quartile 1 ¼ Physical Component Summary (PCS) 12 of 31.5.
c Quartile 2 ¼ PCS 12 of 31.6e38.5.
d Quartile 3 ¼ PCS 12 of 38.6e46.8.
e Quartile 4 ¼ PCS 12 of 46.9.
f Lowest ABI measured.
The Importance of Patients’ Baseline Health Status 217physical health status scores, a similar trend for quartiles of
mental health status was observed as invasive treatment
rates ranged from 37% to 44% in the lowest three mental
health status quartiles to 34% in the highest, but failed to
reach statistical signiﬁcance (p ¼ .43). When considering all
patients’ 1 year health status change scores by pre-
procedural health status scores, a negative correlation be-
tween pre-procedural health status scores and change
scores was observed for patients receiving both invasive
(r ¼ .38, p < .0001) and non-invasive treatment (r ¼ .39;
p < .0001) (Figs. 1 and 2), suggesting that lower pre-
procedural health status scores were associated with im-
provements in patients’ health status at 1 year follow up.
When categorizing patients by quartiles of their pre-
procedural health status scores, patients in the lowest
quartile undergoing invasive treatment had the greatest
health status improvement (change scores ranging from 5.3
for non-invasive treatment to 11.3 for invasive treatment),Figure 1. Scatter plot of 1 year health status change scores by
baseline health status scores. All change scores of individual pa-
tients included in the analyses are presented as a function of the
receipt of invasive (black) versus non-invasive (white) treatment.
Note. PCS ¼ Physical Component Summary score.whereas those in the highest quartile only improved mini-
mally (change scores ranging from 3.0 for non-invasive
treatment to 0.8 for invasive treatment) (Fig. 2).
Patients with pre-procedural health status scores in the
lowest quartile who were treated invasively obtained larger
health status beneﬁts than patients who did not receive
invasive treatment (mean  SD PCS score for invasive
treatment 11.3  10.3 vs. non-invasive treatment 5.3  8.5
[p ¼ .001, Cohen’s D ¼ .5]; NNT ¼ 3 to obtain 0.5 SD
improvement, NNT ¼ 3 to obtain 1 SD improvement). Pa-
tients with pre-procedural health status scores in the
highest quartile had the least beneﬁt when treated inva-
sively (mean  SD PCS score for invasive treatment
0.8  6.3 vs. non-invasive treatment 3.0  8.2 [p ¼ .025,
Cohen’s D ¼ .4]; NNT ¼ 5 to obtain 0.5 SD improvement,Figure 2. Mean  SD changes in 1 year health status scores for
patients that received invasive vs. non-invasive treatment, strati-
ﬁed by quartile categories of baseline health status scores. Note.
Bars represent mean Physical Component Summary (PCS) change
scores and SD for patients undergoing invasive versus non-invasive
treatment. Categories represent baseline quartiles of physical
health status scores for invasive versus non-invasive treatment.
Q1 ¼ lowest quartile; Q4 ¼ highest quartile.
Table 2. Number needed to treat for 1 year clinically relevant
health status improvement (5 or  10 points) for quartiles of
patients’ baseline health status scores, stratiﬁed by invasive
versus non-invasive treatment.
Improvement
5 points NNT 10 points NNT
Quartile 1 3 3
Invasive treatment 34/48 (71) 27/48 (56)
Non-invasive treatment 28/71 (39) 17/71 (24)
Quartile 2 11 9
Invasive treatment 29/52 (56) 21/52 (40)
Non-invasive treatment 31/66 (47) 20/66 (30)
Quartile 3 4 7
Invasive treatment 28/55 (51) 15/55 (27)
Non-invasive treatment 17/64 (27) 9/64 (14)
Quartile 4 5 90
Invasive treatment 8/28 (29) 0/28 (0)
Non-invasive treatment 10/90 (11) 1/90 (1)
Note. Data are given as n/total n (%). NNT ¼ number needed to
treat to obtain 5 points (0.5 SD) or 10 points (1.0 SD)
change in 1 year Physical Component Summary score.
Table 3. The unadjusted and adjusted linear regression model
results for 1 year change in physical health status (B) and 95%
conﬁdence intervals (CIs) are presented.
B 95% CI p
Unadjusted
Invasive treatment 5.49 3.74e7.25 <.0001
Adjusted 1a
Invasive treatment 4.59 2.66e6.51 <.0001
Baseline PCS 12 score 0.36 0.45 to 0.27 <.0001
Adjusted 2b
Invasive treatment 4.57 2.67e6.47 <.0001
Baseline PCS 12 score 0.36 0.45 to 0.27 <.0001
Adjusted 3c
Invasive treatment 4.59 2.71e6.48 <.0001
Baseline PCS 12 score 0.35 0.44 to e0.36 <.0001
Adjusted 4d
Invasive treatment 4.59 2.71e6.48 <.0001
Baseline PCS 12 score 0.40 0.50 to e0.30 <.0001
Adjusted 5e
Invasive treatment 4.44 2.59e6.29 <.0001
Baseline PCS 12 score 0.47 0.55 to 0.34 <.0001
Note. The following variables were sequentially included in the
adjusted models.
a Adjusted model 1 ¼ 1 year treatment strategy (invasive vs. non-
invasive) and baseline Physical Component Summary (PCS) scores.
b adjusted model 2 ¼ model 1 and demographics (age, sex),
hospital site, marital status (partner vs. no partner), educational
background (high school education vs. < high school education).
c adjusted model 3 ¼ model 2 and anatomical lesion location
218 M. van Zitteren et al.NNT ¼ 90 to obtain 1 SD improvement). Similarly, for the
intermediate quartiles, higher proportions of patients
obtaining clinical beneﬁt from invasive treatment were
observed among those who had lower pre-procedural
health status scores (Fig. 2; Table 2).(proximal lesions only, distal lesions only, both proximal and distal
lesion, or non-signiﬁcant lesions), 1 year change in resting ankle
brachial index (ABI; 1 year ABI at rest minus baseline ABI at rest).
d adjusted model 4 ¼ model 3 and cardiac history, cerebrovascular
history, current smoking, diabetes mellitus, body mass index, renal
failure, chronic obstructive pulmonary disease, back pain, and hip
or knee osteoarthritis.
e adjusted model 5 ¼ model 4 and depression. Full model results
are presented in Appendix III.Determinants of 1 year change in self reported physical
health status
Invasive treatment within 1 year of new onset or an exac-
erbation of PAD symptoms was independently associated
with greater improvements in 1 year physical health status
(unadjusted B ¼ 5.49 [p < .0001]; fully adjusted B ¼ 4.44
[p < .0001]) (see Table 3 for stepwise results). Other cor-
relates of greater 1 year health status improvements were
lower pre-procedural health status scores, a younger age,
having a lower ABI, and the absence of depression. The
variables in the fully adjusted model explained 32% of the
total variance, with pre-procedural health status explaining
the most (R2 ¼ 0.22). The interaction between 1 year
treatment strategy and pre-procedural PCS scores was not
included in the model because it failed to reach signiﬁcance
(p ¼ .44). See Appendix III for full model results. Results
were essentially replicated when repeating analyses based
on complete cases (results available from the authors).DISCUSSION
This study is the ﬁrst to prospectively describe 1 year health
status changes following a PAD diagnosis in a cohort of
newly diagnosed patients (Fontaine 2, mild to moderate
symptoms of claudication) in two PAD specialty clinics that
had the infrastructure in place to offer all standard treat-
ment modalities for PAD. While patients with lower pre-
procedural health status scores presented with more
comorbidities, the 1 year health status improvements
following invasive treatment were among the highestcompared with patients having higher pre-procedural
health status scores. In line with the comparisons for the
physical health status scores, a similar trend in mental
health status score comparisons by invasive treatment rates
was observed; however, these observations were not
signiﬁcantly different. Putting these numbers into perspec-
tive, it was calculated that only three patients needed to be
treated invasively in the group with low pre-procedural
health status scores in order for one patient to obtain a
signiﬁcant health status beneﬁt compared with ﬁve patients
among those with high pre-procedural scores. This number
increased to 90 patients when varying the threshold for a
minimal clinically important difference from 0.5 SD to 1 SD,
a threshold that approximates the beneﬁt magnitude
observed in the latest CLEVER (claudication: exercise versus
endoluminal revascularization results) study.2 Undergoing
invasive treatment and pre-procedural health status scores
were important independent correlates of 1 year health
status changes, even while adjusting for important con-
founders. The results were based on observational data,
The Importance of Patients’ Baseline Health Status 219and, as such, further replication of the expected health
status change effects as a function of pre-procedural health
status should occur in the context of controlled clinical trials
evaluating health status beneﬁts following different PAD
treatments.2
Although smaller observational studies conﬁrmed that
invasive treatment in PAD is associated with improvements
in health status changes,4,23,24 none have described health
status changes as a function of pre-procedural health sta-
tus. Having a cohort with newly diagnosed PAD that had
access to non-invasive and invasive options is unique, as the
few studies quantifying health status after revascularization
have been done in procedural cohorts, where patients were
already triaged for invasive treatment,25e28 and no infor-
mation on pre-procedural health status had been
analyzed.27 In addition, as prior studies quantifying invasive
treatment beneﬁts mainly focused on hemodynamic suc-
cess rates,7e9 there is a need to evaluate outcomes that are
more meaningful to the individual patient. This is under-
scored by current guidelines stating that the main PAD
treatment goals are to relieve symptoms and to improve
health status.1,3,29 The present study speciﬁcally focuses on
this goal and provides useful information on expected
health status gains, which will help both patients and cli-
nicians make informed treatment decisions. A longer term
goal for the treatment decision making process in PAD
would be to have information about patients’ pre-
procedural and expected health status outcomes following
different treatment options as assessed by a validated
(disease speciﬁc) health status instrument, while also dis-
cussing potential treatment risks, which could help inform
both the patient and the provider in making a shared,
informed, and evidence based treatment decision.
Prior single center observational studies found an asso-
ciation between undergoing invasive PAD treatment and
improvements in self reported health status.4,23,25e28
However, they did not use pre-procedural patient informa-
tion. Providing such information to patients and clinicians
would be tremendously helpful; currently, they can rely only
on little pre-procedural information in deciding which
treatment would most valuable to the individual, such as
lesion characteristics that may be more amenable to inva-
sive treatment.1,3
After all, all patients undergoing lower extremity endo-
vascular interventions are exposed to procedure related
risks and complications (4e8%),30e32 while serious events
for non-invasive options have rarely been documented.
Beneﬁts can equally be present (improvements in walking
abilities, muscle strength/endurance, and cardiac func-
tion).1,33e35 A free ﬂow of information on risks and beneﬁts,
as well as patients’ preferences, is essential in discussing
treatment options. These efforts will help to improve de-
cision quality in PAD and hopefully design appropriate
criteria for invasive treatment.
Future research is needed to document individual com-
ponents of decision quality in PAD, including a better evi-
dence base on expected risks and beneﬁts for different
therapies and patient preferences. “Parallel”, an agreedupon classiﬁcation system for diagnostic information, is a
prerequisite to standardize the clinical decision process. This
has already been done and is ongoing in coronary artery
disease,36 but is lacking in PAD. Such efforts will help reduce
unwanted treatment variations.
The following limitations should be noted when inter-
preting the results. The generic SF-12 and not a PAD speciﬁc
health status assessment tool was used to assess patients’
self reported health status. Next, patients were recruited
from two vascular specialty clinics in the Netherlands;
therefore, the results may have limited generalizability.
Furthermore, whether or not patients adhered to the ex-
ercise therapy referral and protocol was not systematically
captured in patients’ medical records and, as such, analyses
could not be adjusted for potential non-adherence. Finally,
despite the methodological efforts to adjust for differences
between patients who underwent invasive versus non-
invasive treatment, observational data were relied upon,
and the risk of confounding remains owing to known and
unknown factors. Factors that were not examined in this
study but that may explain allocation to either invasive or
non-invasive therapy are provider, institutional and patient
preferences, ﬁnancial incentives related to reimbursement,
experience of the vascular specialist, and other unknown
comorbidities.
CONCLUSIONS
This study was able to predict which patients will beneﬁt
most from invasive treatment in PAD, based on pre-
procedural information that is both meaningful to pa-
tients and clinicians. Similar to the CLEVER trial results,2
most patients’ health scores improved following invasive
treatment. This was for patients with pre-procedural health
status scores spanning the whole spectrum, although the
beneﬁt magnitude was lower among patients having high
pre-procedural health status scores. Interestingly, these
patients were also the least likely to receive invasive
treatment. The ﬁndings are important to develop further
research that documents expected health status outcomes
as a function of available treatments and by individual pa-
tient characteristics. This information is needed for patients
and clinicians to discuss which treatment would be most
appropriate and preferable to the individual patient.
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ENROLLMENT AND 1 YEAR FOLLOW UP SCHEME.
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IN PHYSICAL HEALTH STATUS (B).B 95% CI p
Invasive treatment 4.44 2.59e6.29 < .0001
Baseline PCS12 L0.45 L0.55 to 0.34 < .0001
Age 0.22 e0.34 to e0.10 < .0001
Male sex 0.75 2.72 to 1.23 .46
Hospital site 0.22 3.71 to 4.15 .91
No partner 0.15 2.40 to 2.10 .90
<High school education 0.32 2.43 to 1.79 .77
Anatomical lesion location 1.08 e2.27 to 0.12 .07
1 year ankle brachial index change L0.08 L0.14 to L0.02 .009
Cardiovascular history 1.09 0.86 to 3.05 .27
Cerebrovascular history 1.45 3.97 to 1.07 .26
Smoking 0.37 2.26 to 1.51 .70
Diabetes mellitus L1.56 L3.75 to 0.63 .16
Obesity (body mass index >30) 1.78 4.10 to 0.54 .13
Renal dysfunction 2.37 5.51 to 0.76 .14
Chronic obstructive pulmonary disease 1.85 4.24 to 0.54 .13
Back pain 0.09 2.76 to 2.58 .95
Hip or knee osteoarthritis 0.95 3.17 to 1.27 .40
Depression L3.17 L5.31 to e1.02 .004
Note. Values in bold indicate statistical signiﬁcance. CI ¼ conﬁdence interval; PCS12 ¼ Physical Component Summary score.REFERENCES
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